HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.
about
Sequencing paediatric antiretroviral therapy in the context of a public health approachSimultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assayGetting to 90-90-90 in paediatric HIV: What is needed?Controlling the HIV/AIDS epidemic: current status and global challengesInduction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland.Effectiveness of first-line antiretroviral therapy and correlates of longitudinal changes in CD4 and viral load among HIV-infected children in Ghana.Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds.The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected childrenManaging HIV-infected children in a low-resource, public clinic: a comparison of nurse vs. clinical officer practices in ART refill, calculation of adherence and subsequent appointments.A Case Series of Acquired Drug Resistance-Associated Mutations in Human Immunodeficiency Virus-Infected Children: An Emerging Public Health Concern in Rural Africa.Development of antiretroviral resistance in children with HIV in low- and middle-income countriesExtensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-line antiretroviral therapy by WHO 2010 guidelines.Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescentsCan combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and ZambiaPooled HIV-1 RNA viral load testing for detection of antiretroviral treatment failure in Kenyan children.Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern.Drug resistance in children at virological failure in a rural KwaZulu-Natal, South Africa, cohort.Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges.Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review.Developments in early diagnosis and therapy of HIV infection in newborns.Suboptimal Viral Suppression Rates Among HIV-Infected Children in Low- and Middle-Income Countries: A Meta-analysis.Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.Special considerations concerning the use of antiretroviral drugs in children.Effectiveness of first-line antiretroviral therapy in HIV/AIDS patients: A 5-year longitudinal evaluation in Fujian Province, Southeast China.Clinical associations of white matter damage in cART-treated HIV-positive children in South Africa.Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing.Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaoundé, Cameroon.Targeting 90-90-90--don't leave children and adolescents behind.The case for viral load testing in adolescents in resource-limited settings."cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies".Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.HIV-1 Drug Resistance in Pre-exposure Prophylaxis TrialsUtilization of dried blood spot specimens can expedite nationwide surveillance of HIV drug resistance in resource-limited settingsClinical, virological and immunological features of HIV-positive children internationally adopted in France from 2005-2015
P2860
Q26774261-89729742-2565-4282-B65C-D63BAD2C6AD6Q28660673-1B26BDC5-3D23-4FBE-AD9A-632BD7ED63EDQ30385352-68600FBF-6DE2-4641-97D6-784EAC549E85Q30420558-C2B31720-17D8-43C1-95E3-EF55DEF129EAQ34215346-816FCF2C-DF63-4700-8F6B-A7D9DDE463F8Q34410947-A7836610-4425-447B-8E18-847A0FE8C53FQ35015853-0F289D85-F3CA-4E3A-9A98-AC4D2D6C1DADQ35547048-0CCAC6DB-5BED-418C-A353-D33E9D05D16EQ36015636-CCDAC264-8167-45E6-BE6A-279B1C6DD016Q36349683-C9268986-FD7F-4DF8-BC0F-DD36AD539F76Q36386846-06FDC2BA-007F-4AEE-AA6D-A6EAD5F934C6Q36488965-0D102F43-9713-4C31-B43A-61F16492A915Q36852631-A2DE5EDD-2B90-46C4-82AC-1944A2B8D344Q36937877-A60C2AA3-6888-48F9-B2DB-EF8AA2EAA2D8Q36941659-52B032BA-A30D-490F-837F-66171C9C6F89Q37083998-18FF202B-A8E6-4AC4-9DD4-AB0AA64DE06EQ37156124-BE640B8C-3596-4286-BD1A-0BCA5B6F9937Q37461250-6E2FEC57-1C4B-4A99-A85B-108AAE42BDAEQ37580891-246355B5-4821-4AEE-B8FB-8B07EAC45040Q37634044-25D25969-1B71-4B50-8448-144FBDEC4343Q38208721-5C562F0E-1DD3-44F9-8193-0FEBD46F3B82Q38648601-86A25B9F-63F0-4622-AA7D-7A49A56A55D1Q38913065-0E11A089-AA38-4646-B37D-FCCA2757F4D1Q40118824-A98EA9CC-464A-4220-A73D-564842758F57Q40223405-C71023AB-F91D-4E1A-9F35-2B541300C7E1Q40535139-A4A1AD6E-9371-4EB2-BFDD-1DE7F7C412E2Q41020993-D4C500CC-41CA-4C7F-A36F-868BBB46CAA2Q41532229-9269821F-2575-425B-8C4C-296A113E44C4Q42215713-80FAEDCC-8A2F-413D-AB9D-B76E5C8743B6Q42620819-43C41CCF-39C7-4022-9939-F70EF05362A2Q43142354-E09AD0B5-1E3F-4149-B0A1-304D7F7071BEQ46391416-50EE4B34-4BF1-4FF4-A01A-7FE6F740D9C0Q46698274-72B8FC13-F378-4364-BC7E-8C295D80AB22Q47133943-D27ACBAE-FB0E-4EB0-920F-BD7A61625AFFQ57207278-38A8BC6D-35F4-462C-BB8E-4903CCB46CDBQ58760170-5C7F24CB-58B9-4383-A536-17762BF28E1AQ59126542-56D6AEF8-924F-4A32-895F-70F64F918E69
P2860
HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
HIV-1-resistance-associated mu ...... regions: a systematic review.
@en
HIV-1-resistance-associated mu ...... regions: a systematic review.
@nl
type
label
HIV-1-resistance-associated mu ...... regions: a systematic review.
@en
HIV-1-resistance-associated mu ...... regions: a systematic review.
@nl
prefLabel
HIV-1-resistance-associated mu ...... regions: a systematic review.
@en
HIV-1-resistance-associated mu ...... regions: a systematic review.
@nl
P2093
P1476
HIV-1-resistance-associated mu ...... regions: a systematic review.
@en
P2093
Job C J Calis
Kim C E Sigaloff
Michèle van Vugt
Sibyl P Geelen
Tobias F Rinke de Wit
P304
P356
10.1016/S1473-3099(11)70141-4
P577
2011-08-25T00:00:00Z